Retatrutide (Amino structure name LY3437943,) is an advanced weight loss peptide compound shown in clinical trials to be vastly superior to Semaglutide, with body-weight reductions exceeding 25% possible.(1) Retatrutide targets agonist activity at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG).(2) While Semaglutide is a GLP-1 receptor agonist, and Tirzepatide is a GLP1/GIP dual agonist, Retatrutide is considered a triagonist due to its activity at GIP, GLP-1, and glucagon.(3) 

Molecule tests Retatrutide from U.S.A based independent labs to ensure purity exceeding 99.5+% (COA). Consumers should use caution with untested or foreign tested research chemicals of dubious purity and quality. 

Product Use Warning: All products are for research use only. Molecule forbids purchase and sale of any product used in human subjects, and Retatrutide is not approved for human use. Molecule supplies Retatrutide to assist researchers in designing and conducting in-vitro or animal (non-human) weight-loss studies and trials for results publication in peer-reviewed journals and other scientific activities. 

Research Citations:

(1) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial: Ania M. Jastreboff, M.D., Ph.D. https://orcid.org/0000-0003-1446-0991, Lee M. Kaplan, M.D., Ph.D., Juan P. Frías, M.D. https://orcid.org/0000-0001-9486-1255, Qiwei Wu, Ph.D., Yu Du, Ph.D., Sirel Gurbuz, M.D., Tamer Coskun, M.D., Ph.D., Axel Haupt, M.D., Ph.D., Zvonko Milicevic, M.D., and Mark L. Hartman, M.D., for the Retatrutide Phase 2 Obesity Trial Investigators.

(2) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock J, Frias J, Jastreboff AM, et al.  Lancet. 2023;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X

(3) The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Urva S, O’Farrell L, Du Y, et al. Diabetes Obes Metab. 2023;25(9):2784-2788. doi: 10.1111/dom.15167